EVP R&D, Chief Medical Officer
Mon, Mar 2, 2026
Mar 2
exercised or converted securities in ALKS
5,000 shares @ $19.34
Increased holdings by +5.40%
Net across this filing: -4.30% (-4,000 shares)
Option Exercise
Sale tied to a same-time option exercise